Presentation

Vicore Pharma is an innovative Swedish research and development company dedicated to creating life-changing treatments for rare lung diseases. Embedded in its approach is the determination to find solutions for conditions which have an enormous deleterious impact on patients and their families and to transform the lives of those affected.

Patients with rare fibrotic lung diseases can suffer from progressive difficulty in breathing and a relentless deterioration in quality of life. Receiving such a diagnosis can be devastating, due to the poor prognosis. The Company appreciate that living with such diseases presents a constant challenge, not only for patients but also for their families and caregivers. Our research and drug development programmes are specifically aimed at alleviating these challenges with the patient at the forefront of our minds.
The ongoing drug development programmes are deeply rooted in the complexities of interstitial lung disease (ILD), in particular fibrotic lung disease. At present, there are no highly effective pharmaceutical treatments for conditions such as idiopathic pulmonary fibrosis (IPF), pulmonary sarcoidosis, or the lung manifestations of systemic sclerosis, all of which are associated with a significant morbidity and mortality. In addition, the symptoms, including dyspnoea and cough (which is severe, persistent, and dry in IPF), rob patients of their ability to breathe.